Biosimilars and Follow-On Biologics Report: The Global Outlook 2009-2024

Questions: Discounts, Updates etc.

Pages: 133

Price (Single): £1499

Price (Departmental): £4999

Price (Company): £6999

Publication Date: 2009-04-09

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

There is great demand for lower-cost biological drugs: commercial and regulatory developments will make biosimilars and follow-on biologics a success – this report explains how

Revenues for biologic drugs reached approximately $125bn in 2008. Patents on most current biologics have expired or will expire during the period 2009 to 2024. In addition, there is mounting pressure from governments, insurers and patients’ groups to reduce costs of pharmaceuticals. Biologic drugs - noted as some of the most-expensive medicines - are major targets for cost savings. The developments facilitating follow-on biologics are gaining momentum, with significant commercial opportunities emerging.

Recently Merck & Co. established a new biosimilar (follow-on biologic or biogeneric) development division; other major pharmaceutical companies plan to follow suit. In March 2009, three new bills on follow-on biologic legislation were introduced to the US Congress. Biosimilars are entering an important period of development. Is your company prepared for the opportunities and threats this will create?  Biosimilars and Follow-On Biologics: The Global Outlook 2009-2024  provides you with essential information to understand this rapidly-emerging market.

This report predicts how the biosimilar market will evolve from 2009 to 2024. We indentify and discuss the biosimilar drugs and manufacturers that will achieve commercial success during the coming fifteen years. Biologic drug classes covered in this report include:

  • Growth hormones
  • Insulin
  • Erythropoietin
  • Colony stimulating factors and interleukin-2 drugs
  • Interferons
  • Monoclonal antibodies
  • Fusion proteins

The biosimilar prospects for each class are examined, biosimilar targets identified and market forecasts to 2024 provided, with extensive supporting information.

Comprehensive analysis of the global market

Using a wealth of research – including detailed sales forecasting, interviews with key opinion leaders and examination of policy documents, reports, industry news, filings and commercial databases – our new study forecasts how the biosimilar market will progress from 2009 to 2024.

Why you should buy Biosimilars and Follow-On Biologics: The Global Outlook 2009-2024

By obtaining your copy of this report, you will benefit from: 

  • Forecasts for the world biosimilar market, leading biosimilar drug types and leading national markets
  • Identification of biologic drugs with potential for commercial biosimilar development
  • Original interviews with biosimilar industry experts, who discuss the present and future of the sector
  • Examination of the driving forces, restraints, competition and opportunities facing commercial stakeholders in the biologic and biosimilar sectors
  • Analysis of biosimilar legislation and regulatory guidance in the US, Europe and Japan – with current and emerging trends discussed
  • Analysis of the biosimilar pipeline – find out what and who will be the leading biosimilar players over the next fifteen years
  • Prediction of where the market is heading - both technologically and commercially - from the present onwards.

The complexity of biologic drugs has retarded development of regulatory frameworks for approval of biosimilars in many countries. The EU was the first major regulatory authority to adopt a procedure allowing regulatory approval of biosimilar medicines. The US awaits a similar legal and regulatory framework. Currently, the FDA can only approve a restricted number of simpler ‘follow-on protein products’. Approval of more-complex biosimilars will necessitate a formal legal and regulatory pathway in the US. The authors of this report believe that the US Congress will approve a biosimilar bill within a few years. In this report, we predict the emergence of biosimilar products in the US, in addition to developments in other major markets during the years ahead.
 

Table of Contents

1 Executive Summary

2 Introduction to Biosimilars

3 The World Biosimilar Market, 2009-2024

4 Issues Affecting the Biosimilars Industry

5 Regional Biosimilar Markets

6 The Biosimilars Pipeline

7 Conclusions

 

List of Tables

 

List of Figures

Other users found this report page using the following search terms: Biosimilars biologics generic biogeneric Monoclonal antibodies Interferon Colony stimulating factor il-2 interleukin-2 Erythropoietin insulin growth hormone biosimilar biosimilars biologics market 2009 drugs global list followon erythropoietin

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.